Circulating Interferon-Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis. by Alunno, Alessia et al.
1 
 
RUNNING HEAD: IFI16 and clinical/serological features in RA 
TITLE: The circulating interferon-inducible protein IFI16 correlates with clinical and 
serological features  in rheumatoid arthritis.  
AUTHORS: Alessia Alunno MD1*, Valeria Caneparo PhD2*, Onelia Bistoni BSc1, Sara 
Caterbi PhD1, Riccardo Terenzi MD1, Marisa Gariglio MD PhD2, Elena Bartoloni MD1, 
Antonio Manzo MD PhD4, Santo Landolfo MD PhD3, Roberto Gerli MD1 
AFFILIATIONS: 1Rheumatology Unit, Department of Medicine, University of Perugia, 
Perugia; 2Department of Translational Medicine, Novara Medical School; 3Department of 
Public Health and Pediatric Sciences, Turin Medical School; 4Division of Rheumatology, 
University of Pavia School of Medicine, Italy. 
*A. Alunno and V. Caneparo equally contributed to this study 
 
CORRESPONDING AUTHOR: Prof. Roberto Gerli, Rheumatology Unit, Department of 
Medicine, University of Perugia, via E. Dal Pozzo snc, I-06127, Perugia, Italy. Phone/Fax 
+39.075.5783975 email: roberto.gerli@unipg.it 
 
FINANCIAL SUPPORT: This study was supported by grant MIUR PRIN 2012 to S.L. 
(2012SNMJRL) 




Objective: The IFN-inducible protein 16 (IFI16) has been detected in sera from patients with 
autoimmune/inflammatory diseases but not in healthy subjects. This leaking leads to loss of 
tolerance towards this self-protein and the development of autoantibodies. In this study,  
clinical significance of both IFI16 protein and anti-IFI16 antibodies (Abs) in rheumatoid 
arthritis (RA) was investigated. 
Methods: IFI16 protein and anti-IFI16 Abs levels were assessed by ELISA in serum samples 
from 154 RA patients and 182 healthy controls (HC), and in synovial fluid (SF) samples from 
21 RA patients and 25 patients with osteoarthritis (OA). 
Results: Mean serum levels for both IFI16 and anti-IFI16 Abs were higher in RA than in HC 
with a direct correlation between IFI16 concentration and anti-IFI16 Abs titer. The majority 
of RA patients with detectable circulating IFI16 protein were also positive for RF/ACPA. The 
latter group was found positive for anti-IFI16 Abs as well. The mean SF concentrations of 
both IFI16 protein and anti-IFI16 Abs were higher in RA when compared with control OA. 
Interestingly, the presence of circulating IFI16 protein, but not anti-IFI16 Abs, significantly 
correlated with RA-associated pulmonary disease. This correlation was not dependent on the 
presence of anti-IFI16 Abs, gender and smoking habit.  
Conclusion: Our data demonstrate that the high levels of circulating IFI16 in RA are more 
frequent in RF/ACPA-positive RA patients and significantly associated with pulmonary 
involvement.  The relevance of circulating IFI16 protein as new clinical biomarker of RA 
should be verified with additional studies.  
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SIGNIFICANCE AND INNOVATION 
- IFI16 protein and anti-IFI16 autoantibodies are highly expressed in the serum and 
synovial fluid of patients with rheumatoid arthritis.  
- Serum IFI16 protein is associated with pulmonary involvement and serological status 





Type I interferons (IFNs) are early mediators of the innate immune response that potentiate 
the adaptive immune response through direct and indirect actions on dendritic cells (DCs), T 
and B cells, and natural killer cells. Increased expression of type I IFN stimulated genes 
(ISGs), namely the “type I IFN signature”, has been described in a variety of autoimmune 
inflammatory disorders (1), including systemic lupus erythematosus (SLE) (2), primary 
Sjögren’s syndrome (pSS) (3), systemic sclerosis (SSc) and rheumatoid arthritis (RA) (4). 
As far as RA is concerned, IFNs have been suggested as pathogenic molecules due to their 
capability to drive a Th1 response (5) but, most intriguingly, the “type I IFN signature” has 
been reported as a marker of disease development and response to therapy. In fact, 
overexpression of some IFN-inducible genes in circulating immune cells has been associated 
with higher risk of developing RA in pre-symptomatic individuals, subjects with arthralgia 
and circulating rheumatoid factor (RF), and/or anti-cyclic citrullinated peptide antibodies 
(ACPA)(6). Moreover, a different baseline gene expression profile of type I ISGs  has been 
associated with DAS28 or EULAR response outcome in RA patients treated with the anti-
tumor necrosis factor (TNF) agents rituximab or tocilizumab(7-9). With this scenario in mind, 
it is intriguing to speculate that “type I IFN signature” may also be able to identify clusters of 
patients with different clinical picture and  prognosis.  
The nuclear phosphoprotein IFI16 is a member of the HIN200/Ifi200 gene family, whose 
overexpression drives early steps of an inflammatory response through NF-kB mediated 
secretion of proinflammatory molecules such as ICAM1, E-selectin, IL-8 and MCP-1(12, 14). 
The IFI16 protein is overexpressed in several systemic autoimmune diseases and its specific 
autoantibodies are prevalent in the sera of these patients, thus linking this autoantigen to the 
pathogenesis of autoimmune diseases (10,13,17). A number of data also indicate the disease 
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specific mislocalization of nuclear IFI16 in several inflammatory settings (11-12) while our 
group has recently demonstrated the occurrence of free IFI16 protein in the sera of 
autoimmune patients (16). Taken together, these observations suggest a role for IFI16 in 
inflammatory, detrimental cellular changes underlying autoimmune phenomena (12, 14).  
Although in a previous study on 15 RA patients the authors failed to show increased levels of 
the IFI16 protein in patients’ sera by comparison with normal controls (15), we have recently 
reported the occurrence of circulating IFI16 protein in patients’ sera suffering from different 
systemic autoimmune disorders, including SSc, SLE, SS and RA (16), Interestingly, RA 
patients displayed the highest levels of circulating protein alongside with the highest 
percentage of subjects with IFI16 levels above the 95th percentile for controls.  
Taken together, these observations prompted us to investigate the prevalence and clinical 
significance of the IFI16 protein and anti-IFI16 autoantibodies in both serum and synovial 




PATIENTS AND METHODS 
Patients. One hundred and fifty four consecutive patients with RA according to the 1987 
American College of Rheumatology criteria (18) were included in the study and 182 sex and 
age-matched healthy donors as controls (HC). At the time of enrollment, serum samples were 
collected and stored at -20°C until use. Twenty-one consecutive RA patients, that underwent 
arthrocentesis for knee arthritis and 25 patients with knee osteoarthritis (OA) requiring 
arthrocentesis were also included in the study for the evaluation of SF samples.  Paired serum 
and SF samples were then obtained from 9 additional RA patients.  Patients receiving intra-
articular medications (e.g corticosteroids, hyaluronic acid) in the previous six months were 
excluded. SF samples were centrifuged and supernatants were stored at -20°C until use. 
Clinical and serological records were collected at the time of enrollment. Pulmonary 
involvement, defined as presence of interstitial lung disease (ILD), was ascertained with X-
ray and high resolution computerized tomography. This study was approved by the local 
Ethics Committee (CEAS) and written informed consent was obtained in accordance with the 
declaration of Helsinki. 
Determination of antibody titers towards human recombinant IFI16 by ELISA. Polystyrene 
micro-well plates (Nunc-Immuno MaxiSorp; Nunc, Roskilde, Denmark) were coated with a 
solution of recombinant IFI16 in PBS. After blocking, sera were added in duplicate. After 
washing, horseradish peroxidase-conjugated rabbit anti-human IgG (Dako Cytomation, 
Carpinteria, CA, USA) was added. Following the addition of the substrate (TMB; KPL, 
Gaithersburg, MD, USA), absorbance was measured at 450 nm, using a microplate reader 
(SpectraCount, Packard, Packard BioScience Company). The background reactivity of the 
reference mixture was substracted to calculate the results. A standard curve was constructed 
by serially diluting IgG from an anti-IFI16 positive patient serum (13, 17).  
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Determination of extracellular IFI16 by capture ELISA. For determination of circulating 
extracellular IFI16 a capture ELISA was employed. Briefly, polystyrene micro-well plates 
(Nunc-Immuno MaxiSorp; Nunc, Roskilde, Denmark) were coated with a home-made 
polyclonal rabbit-anti-IFI16 antibody (aa 478-729). Subsequently, the plates were washed and 
free binding sites were saturated with PBS/0.05% Tween/3% BSA. After blocking, sera were 
added in duplicate. Purified 6His-IFI16 protein was used as standard. BSA served as negative 
control. The samples were washed and in each case monoclonal mouse anti-IFI16 antibody 
(Santa Cruz, sc-8023) was added and incubated for 1h at room temperature. After washing, 
horseradish peroxidase-conjugated anti-mouse antibody (GE Healthcare Europe GmbH, 
Milan, Italy) was added. Following the addition of the substrate (TMB; KPL, Gaithersburg, 
MD, USA), absorbance was measured at 450 nm, using a microplate reader (SpectraCount, 
Packard, Packard BioScience Company). The determination of the concentration was carried 
out using a standard curve for which increasing concentrations of purified 6His-IFI16 were 
used (16).  
Statistical analysis All data analysis was performed using IBM-SPSS version 13.0 (IBM 
Corp. Armonk, NY, USA). As detailed throughout the manuscript, Chi square test,  Mann 
Whitney U test or Kruskal-Wallis test with Dunn’s test for multiple comparison post-hoc 
were employed to compare groups. Univariate and multivariate binary logistic regression 
were employed to identify any association between IFI16 protein/anti-IFI16 antibodies and 





Association of circulating IFI16 protein or anti-IFI16 antibodies with clinical features. 
The presence and levels of the IFI16 protein and anti-IFI16 autoantibodies in serum samples 
from RA patients and healthy controls were assessed by ELISA (for statistical performance 
characteristics of the tests please refer to on line additional material). As shown in Figure 1, 
mean levels of both IFI16 and anti-IFI16 were higher in RA in comparison with HC. 
According to a cut-off value of 27 ng/ml for the IFI16 protein and 113 U/ml for anti-IFI16 
antibody (established as the 95th percentile of the control population) (16, 17), circulating 
IFI16 protein was present in 56/154 (36.4%) RA patients and in 6/116 (5,2%)  HC, while anti-
IFI16 antibodies were observed in 32/154 (20.8%) RA patients and in 9/182 (4.9%) HC, 
confirming a significantly higher prevalence of both protein and autoantibodies in RA (both 
p<0.0001) in comparison with HC. It is worthwhile to mention that among the 56 RA patients 
with circulating IFI16 protein, only 27% were also positive for anti-IFI16 antibodies. In 
contrast, among the 32 patients positive for anti-IFI16 autoantibodies, 47% were also positive 
for the IFI16 protein. Interestingly, while a broad but normal distribution of anti-IFI16 values 
was observed in both RA and HC, the majority of RA samples displayed an intriguing 
distribution of IFI16 levels, being in most of the cases either strongly positive or clearly 
negative. Nevertheless, a significant correlation between IFI16 concentration and anti-IFI16 
antibody titers was observed in the RA patients (Spearman’s rho=0.23; p=0.004). 
When patients were grouped according to the presence or the absence of either IFI16 protein 
or anti-IFI16 antibodies (with the above mentioned respective cut-off), some correlations with 
the clinical features were identified (Table 1). A significantly higher proportion of male 
patients displayed anti-IFI16 antibodies in the absence of circulating IFI16 protein 
(p<0.0003), whereas no correlation with age, age at diagnosis and disease duration was 
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observed. Interestingly, IFI16 protein, but not anti-IFI16 antibodies was closed associated 
with positivity for both RF and anti-CCP antibodies being only 3 out of 56 IFI16-positive 
patients negative for both. Binary logistic regression analysis confirmed the association 
between circulating IFI16 protein and FR/anti-CCP positivity with an odds ratio (OR) of 13 
(95% confidence interval-CI- 4.4-39, p<0.0001). Interestingly, as far as anti-CCP titer was 
concerned, a significant association with IFI16 positivity (OR=1.01, 95% CI= 1.006-1.023, 
p<0.01) was observed. In addition, anti-nuclear antibodies (ANA) were more prevalent in 
IFI16-positive patients compared to those without detectable levels of the protein in the serum 
(39% vs 23%). 
From a clinical point of view, the prevalence of both erosive disease and rheumatoid nodules 
was similar in the patients grouped according to either the presence or absence of IFI16 
protein and anti-IFI16 Abs (Table 1). The disease activity score (DAS) 28, available at the 
time of blood collection for 90 patients, was correlated with neither circulating IFI16 nor anti-
IFI16 antibody titers (p= 0.6 and 0.8 respectively) .  
Interestingly, we found that RA-associated pulmonary disease was significantly associated 
with the presence of circulating IFI16, but not with anti-IFI16 autoantibodies. Since this 
association was found in circulating IFI16-positive patients with or without anti-IFI16 
antibodies, we performed a binary logistic regression in an attempt to quantify the association 
between the presence or absence of IFI16/anti-IFI16 antibodies and pulmonary involvement. 
The OR for pulmonary disease in IFI16-positive patients was 4 (95% confidence interval-
CI=1.6-10.4; p0.003) and was not dependent on the presence of anti-IFI16 antibodies 
(OR=4; 95% CI=1.6-10.2; p0.004). When the same analysis was performed taking into 
account the protein concentration rather than presence/absence of circulating IFI16, it 
appeared that increasing amounts of the protein did not affect the OR for pulmonary 
10 
 
involvement (p=0.06) . It is worthwhile to mention that male gender, smoking and ANA were 
also associated with pulmonary involvement in our study cohort (Table 2). However, a 
multivariate analysis, including the presence of circulating IFI16 protein, revealed that this 
variable was significantly associated with pulmonary involvement independently of   gender, 
smoking habit and ANA positivity. 
Both IFI16 protein and anti-IFI16 antibodies are also present in synovial fluid  
As the main immunopathogenic process in RA takes place in the joints, we were interested to 
verify whether IFI16 protein and/or anti-IFI16 antibodies were also detectable in the SF from 
RA patients. As shown in Figure 2, the mean concentrations of both IFI16 protein (A) and 
anti-IFI16 antibodies (B) in SF were significantly higher in RA patients in comparison with 
the control OA patients, (p≤0.05 and p<0.01, respectively). In both groups, IFI16 and anti-
IFI16 levels were not correlated in SF (p=0.5 and 0.6 respectively)  and no association 
between SF total/differential cell count and levels of either IFI16 or anti-IFI16 antibodies was 
found.  As shown in Figure 2C, the analysis of paired serum and SF samples in RA revealed a 
complete concordance in IFI16 and anti-IFI16 positivity or negativity in the two 




Compelling evidence supports the pathogenic role of IFNs in autoimmune inflammatory 
diseases that are characterized by the overexpression of a number of IFN-inducible genes, 
namely the “IFN signature” (1). Among the molecules encoded by IFN-inducible genes, the 
IFI16 protein has been recently found to be present in sera from patients with a number of 
autoimmune diseases (12). Among these disorders, the highest serum levels of the IFI16 
protein were found in a limited cohort of RA subjects (16). In the present study, we confirm 
in a large cohort of RA patients that they display higher concentrations of circulating IFI16 
protein when compared with HC. Moreover, in contrast to the negative data of a previous 
report, performed in a small number of RA patients and using a 1st generation ELISA (10), we 
have also found statistically significant higher levels of anti-IFI16 antibodies in RA patients 
in comparison with HC by a 2nd generation ELISA with HPLC-purified antigen (13). 
The presence of circulating IFI16 protein in the serum of RA patients is an attractive finding 
that draws a number of considerations. IFI16 is a nuclear pathogen DNA sensor that can be 
mislocalized in the cytoplasm and secreted in the extracellular milieu in several inflammatory 
settings, including virus infections (11, 19). When exposed to the extracellular environment, 
IFI16 is supposed to interact with components of the innate immune response, thereby 
inducing pro-inflammatory molecules (16). In addition, IFI16 overexpression in endothelial 
cells is sufficient to induce apoptosis that is mediated by the simultaneous activation of 
caspase 2 and caspase 3 (14). Taken together, these findings support a role for the IFI16 
protein in the initial steps of the inflammatory process underlying autoimmune disorders, as 
its overexpression, mislocalization and secretion lead to break-down of tolerance towards this 
self-protein and eventually anti-IFI16 antibodies development (11).  
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The immunological relationship between IFI16 autoantigen and its autoreactive antibodies in 
RA  may be supported by  a significant, even if modest, correlation found in the present study. 
However, it is worth mentioning that only a subgroup of RA patients with circulating IFI16 
protein levels above the cut-off were also positive for anti-IFI16 antibodies while a substantial 
number of patients with low or undetectable circulating IFI16 levels displayed significant 
amounts of specific autoantibodies. The presence of both protein and autoantibodies in the 
peripheral blood may be the result of an immune response occurring in inflamed tissues. It 
may be also speculated that a recirculation of B cells from RA target organs into the 
bloodstream can promote their contact with tissue resident cell types that aberrantly display 
IFI16 protein. In RA, the more evident inflammatory processes take place in the synovium. 
Consistent with this assumption, our results show that SF from RA inflamed joints contains 
both the IFI16 protein and anti-IFI16 antibodies and their positivity is closed associated with 
that in the serum. Thus, IFI16-specific B cells may originate in the synovial 
microenvironment following the release of IFI16 by, for example, synovial fibroblasts, 
stimulating the local production of autoantibodies subsequently released in the circulation. 
However, also considering the lack of correlation between IFI16 and anti-IFI16 in SF and the 
demonstration of possible IFI16 positivity in the serum, but not in the SF, we cannot rule out 
that the IFI16-induced immune response may take place in other or additional sites important 
for RA pathogenesis and autoantibody generation, such as the lung. In this context, the 
variable presence of IFI16 protein and/or anti-IFI16 antibodies in the serum may reflect 
different amounts of free protein or autoantibodies released in the bloodstream, explaining the 
presence in some sera of anti-IFI16 with undetectable circulating protein. In addition, it may 
be also hypothesized that in patients with circulating IFI16 protein and lack of anti-IFI16 
antibodies, they will appear in later stages of the disease.  
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According to our data, significant levels of circulating IFI16 protein were detected in about 
one third of our RA population, while anti-IFI16 autoantibodies were present in about 20% of 
the them. IFI16 protein release appears to be specifically associated with RA patients 
displaying circulating RF/anti-CCP antibodies. These findings deserve some comments: i) 
IFI16-induced inflammation in RA appears to be more relevant in patients developing 
autoimmune reactions against not only citrullinated proteins, but also nuclear autoantigens. It 
may be intriguing to verify if the few IFI16 positive patients without other detectable 
circulating autoantibodies display antibodies against carbamylated proteins that seem to 
represent an alternative RA biomarker with a possible pathogenic role independent of anti-
CCP;  ii) RA patients with circulating RF and, particularly, anti-CCP antibodies, are more 
prone to develop extra-articular manifestation of the disease, including pulmonary 
involvement (20); iii) the observed association between circulating IFI16 protein and lung 
manifestation, irrespective of the presence of anti-IFI16 antibodies, appears to fit well in the 
context of seropositive RA patient subset that displays very high risk of pulmonary disease 
(21); iv) the previously reported association between pulmonary involvement, male gender 
and smoking is also confirmed in this study (22), although circulating IFI16 protein was 
independently associated with lung involvement.  
In the present study, anti-IFI16 antibodies, but not the IFI16 protein, were more prevalent in 
male gender. Previous reports indicate that anti-IFI16 antibodies may exert a protective rather 
than proinflammatory role in autoimmune disorders (10, 13, 17); if this can be considered as 
an attempt of the immune system to defend tissues against a stronger and more aggressive 
inflammatory process, as occurs in RA males, remains a matter of debate. Other intriguing 
questions, however, arise from the close relationship between gender, smoking and lung 
disease in RA from a pathogenic point of view. It has been hypothesized that the increased 
frequency of RA-related pulmonary manifestations in men may be due to more prevalent and 
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higher consumption of tobacco (22). Tobacco smoking, in fact, may precipitate site-specific 
citrullination in the lungs leading to the generation of anti-CCP antibodies (23). This process, 
that may occur very early in RA even before disease onset (24), appears to play a key role in 
triggering and perpetuating RA inflammation thus representing a pathogenic link with the 
proinflammatory role exerted by the  IFI16 protein. The fact that RA lung involvement was 
associated with circulating IFI16 positivity, but didn’t correlate with the serum levels of the 
protein, is not surprising since the great majority of IFI16-positive patients displayed very 
high levels of the protein. Accordingly, RA pulmonary manifestations are usually associated 
with very high titers of anti-CCP (22). 
Altogether, the results of this study confirm the occurrence of the nuclear DNA sensor IFI16 
protein in RA patients’ sera. This autoantigen is more prevalent in subjects with circulating 
RF/anti-CCP antibodies and may mirror its involvement in inflammatory process in target 
tissues. Although IFI16 can be detected in inflamed joints, it does not seem to be associated 
with joint disease activity or erosions. Although the observed significant association with lung 
involvement suggests an important pathogenic role in the inflammatory processes 
characterizing RA, the clinical and prognostic significance of circulating IFI16 protein in this 
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Figure 1 Expression of the IFI16 protein (A) and anti-IFI16 antibodies (B) in the serum of 
HC (n. 116 and n. 182, respectively) and RA patients (n. 154). Bars indicate mean values. 
Dotted lines mark cut-off levels of positivity as determined by the 95th percentile of the 
control population. P values were calculated with Mann Whitney U test.  
Figure 2 Expression of the IFI16 protein (A) and anti-IFI16 antibodies (B) in the synovial 
fluid of OA (n. 25) and RA patients (n. 21). C) Expression of the IFI16 protein and anti-IFI16 
antibodies in 9 paired samples of serum and synovial fluid of RA patients. Bars indicate mean 
values. Dotted lines mark cut-off levels of positivity as determined by the 95th percentile of 




















   All IFI16 pos IFI16 neg p anti-IFI16 pos anti-IFI16 neg p 
Number of RA patients  154 56 (36) 98 (64) na 32 (21) 122 (79) na 
Male 27 (17) 12 (21) 15 (15) 0.4 10 (31) 7 (6) 0.0003 
Age  64±1 64±2 64±1 0.5 66±2 63±1 0.3 
Age at diagnosis  52±1 53±2 51±1 0.9 53±2 51±1 0.9 
Disease duration  13±0.7 12±1 14±0.9 0.7 14±2 13±0.8 0.9 
Autoantibodies  
       
           none  42 (27) 3 (5) 39 (40) <0.0001 5 (16) 37 (30) 0.1 
RF+ 19 (12) 7 (12) 12 (12) 0.8 5 (16) 14 (11) 0.5 
anti-CCP+ 9 (6) 1 (2) 8 (8) 0.1 2 (6) 7 (6) 0.7 
RF+/anti CCP+ 84 (55) 45 (81) 39 (40) <0.0001 20 (62) 64 (53) 0.3 
           ANA+  45 (29) 22 (39) 23 (23) 0.04 13 (41) 32 (26) 0.1 
Erosions  83 (54) 35 (62) 48 (49) 0.1 14 (44) 69 (56) 0.2 
Nodules  10 (6) 5 (9) 5 (5) 0.5 4 (12) 5 (4) 0.08 
Pulmonary involvement  23 (15) 15 (27) 8 (8) 0.004 6 (19) 17 (14) 0.6 
RF, rheumatoid factor, CCP, cyclic citrullinated peptide, ANA, anti-nuclear antibodies, pos, positive, neg, 




Table 2. Univariate and multivariate binary logistic regression analysis of factors associated 











 Univariate Multivariate 
Variable OR 95% CI p value OR 95% CI p value 
Male gender 4 1.5-10.6 0.005 2.7 0.9-8.3 0.08 
Smoking* 2.8 1.1-7.5 0.04 1.6 0.5-4.9 0.4 
ANA 2.6 1.04-6.4 0.04 2.07 0.7-5.8 0.2 
IFI-16 4 1.6-10.4 0.003 3.1 1.1-8.7 0.03 





















Table 3. Statistical performance characteristics of Anti-IFI16 and IFI16 assessment in 
rheumatoid arthritis.  
 
 Anti-IFI16 autoantibodies IFI16 protein 
Sensitivity 20.78% 36.30% 
Specificity 95.05% 94.80% 
Positive predictive value 78.05% 90.30% 
Negative predictive value 58.64% 52.88% 
 
 
 
 
 
 
 
 
